


## NSC693868

Cat. No.:	HY-103381
CAS No.:	40254-90-8
Molecular Formula:	C <sub>9</sub> H <sub>7</sub> N <sub>5</sub>
Molecular Weight:	185.19
Target:	CDK; GSK-3
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 5 mg/mL (27.00 mM; Need ultrasonic and warming)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM	5.3999 mL	26.9993 mL	53.9986 mL	
		5 mM	1.0800 mL	5.3999 mL	10.7997 mL	
		10 mM	0.5400 mL	2.6999 mL	5.3999 mL	
Please refer to the solubility information to select the appropriate solvent.						

### BIOLOGICAL ACTIVITY

Description	NSC693868 is a selective inhibitor of CDK1 and CDK5 with IC <sub>50</sub> s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC <sub>50</sub> of 1 μM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways <sup>[1]</sup> .					
IC <sub>50</sub> & Target	Cdk1/cyclin B 600 nM (IC <sub>50</sub> )	Cdk5/p25 400 nM (IC <sub>50</sub> )	GSK-3β 1 μM (IC <sub>50</sub> )			

### REFERENCES

[1]. Ortega MA, et al. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg Med Chem. 2002 Jul;10(7):2177-84.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA